• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Israeli AI Clinical Insight Company Medial Earlysign Partners with Datos Health

Share:

March 17, 2021

Israeli remote care automation company, Datos Health has announced a collaboration with AI-based clinical insights provider, Medial EarlySign to offer an integrated platform that identifies high-risk patients who would benefit from remote care programmes.

WHY IT MATTERS

Combining both companies’ core technologies, the partnership aims to help providers achieve better outcomes in vulnerable populations, as they transition to value-based care.

The collaboration combines EarlySign’s predictive solutions for identifying patients at increased risk of chronic or life-threatening conditions with Datos’s corresponding automated remote care programmes, helping to prevent or delay the onset of disease and downstream complications.

The introduction of this solution is significant during the pandemic as high-risk population management becomes crucial for healthcare providers and the delivery of preventative services increases in demand.

THE LARGER CONTEXT

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Last year, Datos partnered with Vaica Medical to include medication adherence information as part of Datos’s offering of patient data. The solution was implemented at Israel’s Sheba Medical Center.

At the beginning of the pandemic, Datos’s remote patient monitoring platform, Tyto Care’s connected devices, and a robot from InTouch Health helped Sheba Hospital treat and monitor patients in quarantine and at home.

ON THE RECORD

Ori Geva, CEO and co-founder of Medial EarlySign said: “The transition to value-based care and pre-emptive approaches requires deeper insight into the patient population. Medial EarlySign’s AI-based clinical approach facilitates proactive and preventative treatment through earlier identification of high-risk patient trajectories when interventions stand more chance of halting or preventing the onset of disease.

“Datos provides healthcare stakeholders new options and models of intervention for these high-risk patients, including a way to seamlessly enable more frequent, or even continuous monitoring and engagement that can reduce intervention costs and significantly improve care delivery and patient outcomes.”

Uri Bettesh, CEO and founder of Datos Health said: “Datos has spent the last several years focused on building a solution for personalised and automated remote care across a diverse range of disease conditions, enabling better care and a higher level of patient engagement and participation.

“The prospect of extending automated remote care to pre-disease and early onset stages opens up a new world of possibilities for the ultimate goal of keeping people healthier for longer.”

Source: Mobihealth News

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Emerging Growth Frontiers in Single-Cell Analysis MarketEmerging Growth Frontiers in Single-Cell Analysis Market
  • Insights on the Dry Type Transformer Global Market to 2028 – 3D Core Dry Type Transformer Applications Presents Opportunities – ResearchandMarkets.comInsights on the Dry Type Transformer Global Market to 2028 – 3D Core Dry Type Transformer Applications Presents Opportunities – ResearchandMarkets.com
  • Addiction Focused Startup Quit Genius Scores $11M in Series A FundingAddiction Focused Startup Quit Genius Scores $11M in Series A Funding
  • Arch Biopartners Receives Funding for Development of LSALT Peptide Drug ProgramArch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
  • Amedisys Shareholders Approve $3.3B UnitedHealth Union.Amedisys Shareholders Approve $3.3B UnitedHealth Union.
  • R1 Expands Revenue Cycle Management Offering to More Medical GroupsR1 Expands Revenue Cycle Management Offering to More Medical Groups
  • Paratek Pharmaceuticals Up 20% On Takeout Speculation – ReportParatek Pharmaceuticals Up 20% On Takeout Speculation – Report
  • ApolloMD Partners with Cedar to Implement Optimized Online Patient Billing ExperienceApolloMD Partners with Cedar to Implement Optimized Online Patient Billing Experience

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications